Trulieve Cannabis (TRLV) Fundamentals 2026 — Revenue Analysis | SniperIQ
Trulieve Cannabis (TRLV) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Trulieve Cannabis's market cap?
Trulieve Cannabis (TRLV) has a market capitalization of approximately
What is Trulieve Cannabis's P/E ratio?
Trulieve Cannabis's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Trulieve Cannabis?
Trulieve Cannabis runs a net profit margin of -6.9%, a gross margin of 59.7%, and an operating margin of 12.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Trulieve Cannabis generate?
Trulieve Cannabis reported revenue of
Does Trulieve Cannabis pay a dividend?
Trulieve Cannabis does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Trulieve Cannabis financially healthy?
Trulieve Cannabis carries a debt-to-equity ratio of 0.54x and a current ratio of 5.26x, with a market beta of 1.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Trulieve Cannabis a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Trulieve Cannabis (TRLV) the key facts are: market cap
Track Trulieve Cannabis's full fundamentals live
Get Trulieve Cannabis's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.